HLS Therapeutics Inc
TSX:HLS

Watchlist Manager
HLS Therapeutics Inc Logo
HLS Therapeutics Inc
TSX:HLS
Watchlist
Price: 3.85 CAD 1.32%
Market Cap: 122.4m CAD
Have any thoughts about
HLS Therapeutics Inc?
Write Note

HLS Therapeutics Inc
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

HLS Therapeutics Inc
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
HLS Therapeutics Inc
TSX:HLS
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

HLS Therapeutics Inc
Glance View

Market Cap
122.4m CAD
Industry
Health Care

HLS Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The firm is focused on developing clinically differentiated pharmaceutical products in the specialty central nervous system (CNS) and cardiovascular (CV) markets. Its products include Vascepa, Trinomia, Clozaril, CSAN Pronto, PERSERIS and MyCare Psychiatry/MyCare Insite. Its lead product, Clozaril, is an atypical antipsychotic indicated in the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules reduce the risk of cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina in statin-treated patients with elevated triglycerides.

HLS Intrinsic Value
6.14 CAD
Undervaluation 37%
Intrinsic Value
Price

See Also

Back to Top